Literature DB >> 3511049

The major excreted protein of transformed fibroblasts is an activable acid-protease.

S Gal, M M Gottesman.   

Abstract

Malignant transformation of mouse cells by a variety of agents or treatment with the tumor promoter 12-O-tetradecanoylphorbol 13-acetate or platelet-derived growth factor results in increased synthesis and secretion of a 39,000-dalton protein termed major excreted protein (MEP). We report here that secreted MEP is an acid-activable protease. The secreted precursor form of the protease is auto-activated at low pH and is able to digest a variety of proteins, including the extracellular matrix proteins fibronectin, collagen, and laminin. MEP protease activity has pH optimum of 3.3-3.6 and is temperature- and concentration-dependent. The activity is inhibited by sulfhydryl protease inhibitors such as leupeptin and iodoacetic acid and not by metallo-, seryl-, or carboxyprotease inhibitors. The MEP-derived protease has characteristics distinct from the cathepsins previously reported and thus may be a new acid-protease of mouse cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3511049

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

2.  Inhibitor studies indicate that active cathepsin L is probably essential to its own processing in cultured fibroblasts.

Authors:  A Salminen; M M Gottesman
Journal:  Biochem J       Date:  1990-11-15       Impact factor: 3.857

Review 3.  The early and late processing of lysosomal enzymes: proteolysis and compartmentation.

Authors:  A Hasilik
Journal:  Experientia       Date:  1992-02-15

4.  The application of a novel biotinylated affinity label for the detection of a cathepsin B-like precursor produced by breast-tumour cells in culture.

Authors:  B M Cullen; I M Halliday; G Kay; J Nelson; B Walker
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

5.  Inhibition of epidermal growth factor receptor biosynthesis caused by the src oncogene product, pp60v-src.

Authors:  W J Wasilenko; M Nori; N Testerman; M J Weber
Journal:  Mol Cell Biol       Date:  1990-03       Impact factor: 4.272

6.  Cathepsins D, B, and L in transformed human breast epithelial cells.

Authors:  T T Lah; G Calaf; E Kalman; B G Shinde; R Somers; S Estrada; E Salero; J Russo; I Daskal
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

7.  Inflammatory mediators regulate cathepsin S in macrophages and microglia: A role in attenuating heparan sulfate interactions.

Authors:  J P Liuzzo; S S Petanceska; D Moscatelli; L A Devi
Journal:  Mol Med       Date:  1999-05       Impact factor: 6.354

8.  Participation of multiple factors, including proliferin, in the inhibition of myogenic differentiation.

Authors:  E L Wilder; D I Linzer
Journal:  Mol Cell Biol       Date:  1989-02       Impact factor: 4.272

9.  Sequence and expression of the cDNA for MEP (major excreted protein), a transformation-regulated secreted cathepsin.

Authors:  B R Troen; S Gal; M M Gottesman
Journal:  Biochem J       Date:  1987-09-15       Impact factor: 3.857

10.  Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma.

Authors:  Angelo Agathanggelou; Ivan Bièche; Jalal Ahmed-Choudhury; Barbara Nicke; Reinhard Dammann; Shairaz Baksh; Boning Gao; John D Minna; Julian Downward; Eamonn R Maher; Farida Latif
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.